FDA Approves Qutenza for PHN
NeruogesX Inc. announced in November that the Food and Drug Administration has approved Qutenza (capsaicin) 8% patch for the management of neuropathic pain as a result of postherpetic neuralgia (PHN). This is the only product to be approved so far that contains prescription strength capsaicin.
PHN is nerve pain that can occur following shingles. Shingles can damage nerves and the pain from this nerve damage is sharp, burning, tingling shooting or even numb in sensation. It can persist after the attack of shingles has cleared up disrupting the life of the victim. The risk of PHN increases with age and in those who experienced sharp pain or a severe rash during the episode of shingles.
Qutenza delivers medication through a dermal delivery system to provide up to three months of pain relief after a single hour application. The nerves are targeted in the area of skin where the patient feels pain. The patch is applied by a healthcare professional and up to four patches may be used at the same time. Reports state it is a non-narcotic, locally acting and will not cause drowsiness or have adverse drug interactions.
Common side effects during clinical trials include:
- Site redness
Serious adverse reactions included application site pain and increased blood pressure. Blood pressure increases occurred during or just after exposure to Qutenza and lasted for around two hours after the patch was removed.
If you or a loved one has taken Qutenza and developed these or other adverse reactions, please contact the experienced pharmaceutical litigation attorneys at Schlichter, Bogard & Denton today for a case consultation. We serve the Kansas City, Missouri area, as well as clients nationwide.